Cargando…
A Possible Novel Effect for Dapagliflozin in the Management of Subcutaneous Insulin Resistance Syndrome: A Report of Two Cases
INTRODUCTION: Subcutaneous insulin resistance syndrome (SIRS) is a rare condition in which patients poorly respond to subcutaneous (SC) insulin but maintain a normal response to intravenous (IV) insulin. The underlying pathophysiology remains elusive. Several treatment regimens have been tested for...
Autores principales: | Sweis, Nabil W. G., Albanna, Ahmad, Alhasoun, Rama, Zayed, Ayman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Brieflands
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661541/ https://www.ncbi.nlm.nih.gov/pubmed/36407033 http://dx.doi.org/10.5812/ijem-126350 |
Ejemplares similares
-
Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance
por: Taberner-Cortés, Alida, et al.
Publicado: (2020) -
Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report
por: Martínez-Montoro, José Ignacio, et al.
Publicado: (2022) -
Dapagliflozin's effect on serum homocysteine in patients with hypertension complicated with insulin resistance
por: Yu, Xiaoqian, et al.
Publicado: (2023) -
Case of subcutaneous insulin resistance syndrome treated with ultra‐rapid insulin lispro
por: Ishii, Takahiro, et al.
Publicado: (2021) -
Effıcacy and safety of dapagliflozin on diabetic patients receiving high-doses of insulin
por: Sertbas, Meltem, et al.
Publicado: (2019)